Clinical trials: ST-segment Elevation Myocardial Infarction (STEMI)
ST-segment Elevation Myocardial Infarction (STEMI)
Effect of Remote Ischemic Conditioning in Heart Attack Patients
New treatments are required to improve health outcomes in patients with ischemic heart disease. This is especially so in developing countries such as Mauritius in which optimal therapy for acute myocardial infarction may not be…
- Trial name
- ERIC-LYSIS (NCT02197117)
- Testing
- Remote ischemic conditioning, Control
- Where
- 5 sites in Mauritius
- Volunteers
- 519 people
- Sponsor
- University College, London
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
Acute Myocardial Infarction, Antiplatelet Therapy
Platelet Inhibition in the Acute Phase of STEMI
Background: Dual antithrombotic treatment with aspirin and clopidogrel is recommended in patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Acute Myocardial Infarction, Antiplatelet Therapy, ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT01144819
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
ST-segment Elevation Myocardial Infarction (STEMI)
Pharmacoinvasive Therapy With Prourokinase
The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)
- Trial name
- NCT01642667
- Testing
- Prourokinase
- Where
- China
- Volunteers
- 197 people
- Sponsor
- Suzhou Landing Pharmaceuticals